Hiroaki Matsubara, a former Kyoto Prefectural University cardiology researcher who resigned last year following an investigation, has had another paper retracted, his ninth.
Here’s the notice from Arteriosclerosis, Thrombosis, and Vascular Biology:
For the article by Asako Katsume, Mitsuhiko Okigaki, Akihiro Matsui, Jishan Che, Yasushi Adachi, Eigo Kishita, Shinichiro Yamaguchi, Koji Ikeda, Tomomi Ueyama, Satoaki Matoba, Hiroyuki Yamada, and Hiroaki Matsubara (Early inflammatory reactions in atherosclerosis are induced by proline-rich tyrosine kinase/reactive oxygen species–mediated release of tumor necrosis factor-α and subsequent activation of the p21Cip1/Ets-1/p300 system. Arterioscler Thromb Vasc Biol. 2011;31:1084–1092; DOI: 10.1161/ATVBAHA.110.221804), after an investigation by the Kyoto Prefectural University of Medicine Investigation Committee, the Committee found figures in the referenced article were falsified by Dr. Okigaki.
The editors, therefore, hereby retract the article.
Okigaki appears to be an author on just one of Matsubura’s eight other retracted papers.
The Arteriosclerosis, Thrombosis, and Vascular Biology paper has been cited 11 times, according to Thomson Scientific’s Web of Knowledge. As we’ve noted:
Matsubara has been part of what has become a complicated story involving Novartis, whose drug valsartan (Diovan) was the subject of the now-retracted Kyoto Heart Study, which Matsubara led.